title: CIGB-247: a VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors.
abstract: CIGB-247 is a novel cancer therapeutic vaccine that uses a mutated form of human VEGF as antigen. Being metastatic disease the most dramatic factor of tumor biology affecting patient survival and cure, preclinical evaluation of the impact of CIGB-247 vaccination on experimental metastasis mouse models is highly relevant, and constitutes the focus of this work. CIGB-247 was administered in a weekly schedule known to effectively reduce primary tumor growth. The vaccine was tested in experimental and spontaneous metastasis models of colon (CT26), lung (3LL-D122) and breast (F3II) carcinomas growing in C57Bl/6 or BALB/c mice. Primary tumor growth parameters, metastatic counts, and/or animal survival were recorded. Histology and specific humoral and cellular responses to the vaccine were evaluated. As compared to control groups, CIGB-247 vaccination significantly reduced the number and size of metastatic tumor foci in lungs after intravenous inoculation of CT26 and 3LL-D122 tumor cells. Spontaneous lung dissemination from 3LL-D122 and F3II breast tumor cells implanted in the footpad, or subcutaneously, was also reduced by immunization with CIGB-247. The vaccine elicited in both mouse strains antibodies specific for human and murine VEGF that effectively blocked the interaction of VEGF with VEGF receptor 2. Differing from other experimental reports that describe the use of VEGF for active tumor immunotherapy, CIGB-247 elicited a specific cellular response, measured both by a DTH increment and the induction of spleen cells cytotoxic to syngeneic tumor cells producing murine VEGF. In summary our results reinforce the potential of CIGB-247 vaccination to reduce both tumor growth and the number and size of tumor metastasis in lungs, the latter both after direct inoculations of cells in the blood stream, or as part of primary tumor progression in immunocompetent mice.
authors.affiliation: Cancer Immunotherapy Laboratory, Department of Pharmaceuticals, and Animal Facility, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Playa Cubanacán, Havana 10600, Cuba. monica.bequet@cigb.edu.cu
authors.forename: Mónica
authors.initials: M
authors.lastname: Bequet-Romero
authors.forename: Yanelys
authors.initials: Y
authors.lastname: Morera
authors.forename: Marta
authors.initials: M
authors.lastname: Ayala-Ávila
authors.forename: Julio
authors.initials: J
authors.lastname: Ancizar
authors.forename: Yordanka
authors.initials: Y
authors.lastname: Soria
authors.forename: Aracelys
authors.initials: A
authors.lastname: Blanco
authors.forename: Jesús
authors.initials: J
authors.lastname: Suárez-Alba
authors.forename: Jorge V
authors.initials: JV
authors.lastname: Gavilondo
mesh_terms: D000818:Animals; D000912:Antibodies, Neoplasm / Q000097:blood; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D056724:Immunity, Humoral; D016233:Immunotherapy, Active; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy; D040262:Receptors, Vascular Endothelial Growth Factor / Q000378:metabolism; D011994:Recombinant Proteins / Q000276:immunology; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology*
chemical_list: D000912:Antibodies, Neoplasm; D019496:Cancer Vaccines; D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A; D040262:Receptors, Vascular Endothelial Growth Factor